KEYNOTE-012: Long-lasting responses in a phase Ib study of pembrolizumab for metastatic triple-negative breast cancer (mTNBC)

被引：13
|
作者：
Nanda, R.
Specht, J.
Dees, C.
Berger, R.
Gupta, S.
Geva, R.
Pusztai, L.
Pathiraja, K.
Ray, A.
Karantza, V.
Buisseret, L.
机构：
[1] Univ Chicago, Chicago, IL 60637 USA
[2] Univ Washington, Seattle, WA 98195 USA
[3] Univ North Carolina Lineberger Comprehens Canc Ct, Chapel Hill, NC USA
[4] Sheba Med Ctr, Tel Hashomer, Israel
[5] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[6] Tel Aviv Sourasky Med Ctr, Tel Aviv, Israel
[7] Yale Univ Sch Med, New Haven, CT 06520 USA
[8] Merck & Co Inc, Kenilworth, NJ USA
[9] Univ Libre Bruxelles, Inst Jules Bordet, Brussels, Belgium
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.SABCS16-P6-10-03
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P6-10-03
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Metastatic triple-negative Breast Cancer (mTNBC) First-in-class Therapy with Sacituzumab Govitecan
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (1-2) : 64 - 65
  • [42] A phase II, single arm study assessing the efficacy of pembrolizumab (Pembro) plus radiotherapy (RT) in metastatic triple negative breast cancer (mTNBC)
    McArthur, Heather L.
    Barker, Christopher Andrew
    Gucalp, Ayca
    Lebron-Zapata, Lizza
    Wen, Yong Hannah
    Kallman, Cindy
    D'Agnolo, Alessandro
    Rodine, Micaela
    Arnold, Brittany
    Zhang, Zhigang
    Ho, Alice Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [43] Pilot study of carboplatin, nab-paclitaxel and pembrolizumab for metastatic triple-negative breast cancer
    Baar, Joseph
    Abraham, Jame
    Budd, G. Thomas
    Silverman, Paula
    Montero, Alberto
    Moore, Halle
    Fu, Pingfu
    Varadan, Vinay
    Ladaika, Kara
    Hricik, Lauren
    CANCER RESEARCH, 2021, 81 (04)
  • [44] A phase II trial of stereotactic radiation therapy and in situ oncolytic virus therapy in metastatic triple-negative breast cancer (mTNBC) patients followed by pembrolizumab (STOMP).
    Sun, Kai
    Ensor, Joe E.
    Xu, Yitian
    Zhang, Licheng
    Guerrero, Carlo
    Niravath, Polly Ann
    Patel, Tejal Amar
    Geyer, Charles E.
    Jain, Dharamvir
    Teh, Bin S.
    Farach, Andrew M.
    Sultenfuss, Mark
    Gupta, Nakul
    Schwartz, Mary R.
    Haley, Susan
    Mejia, Jamie
    Butler, E. Brian
    Bernicker, Eric
    Chen, Shu-Hsia
    Chang, Jenny Chee Ning
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [45] Association of tumor mutational burden (TMB) and clinical outcomes with pembrolizumab (pembro) versus chemotherapy (chemo) in patients with metastatic triple-negative breast cancer (mTNBC) from KEYNOTE-119.
    Winer, Eric P.
    Lipatov, Oleg
    Im, Seock-Ah
    Goncalves, Anthony
    Munoz-Couselo, Eva
    Lee, Keun Seok
    Schmid, Peter
    Testa, Laura
    Witzel, Isabell
    Ohtani, Shoichiro
    Lunceford, Jared
    Karantza, Vassiliki
    Mejia, Jaime Alberto
    Cristescu, Razvan
    Aurora-Garg, Deepti
    Jelinic, Petar
    Huang, Lingkang
    Cortes, Javier
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [46] Phase I/I study of niraparib plus pembrolizumab in patients with triple-negative breast cancer or recurrent ovarian cancer (KEYNOTE-162).
    Konstantinopoulos, Panagiotis
    Moore, Kathleen N.
    Sachdev, Jasgit C.
    Mita, Monica M.
    Vinayak, Shaveta
    Seward, Shelly Marie
    Karantza, Vassiliki
    Aktan, Gursel
    Ferguson, Andrew
    Bobilev, Dmitri
    Matulonis, Ursula A.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [47] Immunogenicity and efficacy of pembrolizumab and doxorubicin in a phase I trial for patients with metastatic triple-negative breast cancer
    Colt A. Egelston
    Weihua Guo
    Susan E. Yost
    Xuan Ge
    Jin Sun Lee
    Paul H. Frankel
    Yujie Cui
    Christopher Ruel
    Daniel Schmolze
    Mireya Murga
    Aileen Tang
    Norma Martinez
    Misagh Karimi
    George Somlo
    Peter P. Lee
    James R. Waisman
    Yuan Yuan
    Cancer Immunology, Immunotherapy, 2023, 72 : 3013 - 3027
  • [48] Immunogenicity and efficacy of pembrolizumab and doxorubicin in a phase I trial for patients with metastatic triple-negative breast cancer
    Egelston, Colt A.
    Guo, Weihua
    Yost, Susan E.
    Ge, Xuan
    Lee, Jin Sun
    Frankel, Paul H.
    Cui, Yujie
    Ruel, Christopher
    Schmolze, Daniel
    Murga, Mireya
    Tang, Aileen
    Martinez, Norma
    Karimi, Misagh
    Somlo, George
    Lee, Peter P.
    Waisman, James R.
    Yuan, Yuan
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2023, 72 (09) : 3013 - 3027
  • [49] KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy for previously untreated, locally recurrent, inoperable or metastatic triple-negative breast cancer (mTNBC)
    Cortes, Javier
    Guo, Zifang
    Karantza, Vassiliki
    Aktan, Gursel
    CANCER RESEARCH, 2017, 77
  • [50] Phase 2 study of pembrolizumab as first-line therapy for PD-L1-positive metastatic triple-negative breast cancer (mTNBC): Preliminary data from KEYNOTE-086 cohort B.
    Adams, Sylvia
    Loi, Sherene
    Toppmeyer, Deborah
    Cescon, David W.
    De laurentiis, Michele
    Nanda, Rita
    Winer, Eric P.
    Mukai, Hirofumi
    Tamura, Kenji
    Armstrong, Anne
    Liu, Minetta C.
    Iwata, Hiroji
    Ryvo, Larisa
    Wimberger, Pauline
    Card, Deborah
    Ding, Yu
    Karantza, Vassiliki
    Schmid, Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345